|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 8,410,103
United States Patent 8,410,103, granted on April 2, 2013, to Merck Sharp & Dohme Corp., covers novel 2-amino-1,3,4-thiadiazole derivatives and their use in treating protein tyrosine phosphatase 1B (PTP1B) related disorders. The patent asserts broad claims over a genus of compounds and specific methods of treatment.
What is the core invention claimed in US Patent 8,410,103?
The patent's core invention resides in a specific class of chemical compounds characterized by a 2-amino-1,3,4-thiadiazole nucleus. These compounds are designed to inhibit the activity of PTP1B, an enzyme implicated in insulin resistance and cellular signaling pathways.
Claim 1, the broadest independent claim, defines a genus of compounds with the following general structure:
R1
|
N--C--N
/ \ / \
S---C C---R2
\ /
N
Where:
- R1 is selected from a defined list of substituents, including, but not limited to, hydrogen, alkyl, haloalkyl, cycloalkyl, phenyl, substituted phenyl, heteroaryl, and heterocyclyl.
- R2 is selected from a defined list of substituents, including, but not limited to, alkyl, haloalkyl, cycloalkyl, phenyl, substituted phenyl, heteroaryl, and heterocyclyl.
- The thiadiazole ring may be substituted.
The patent further claims specific compounds within this genus, pharmaceutical compositions containing these compounds, and methods of treating PTP1B-related disorders using these compounds.
What specific disorders are targeted by the patent claims?
The patent claims methods of treating disorders that involve or are associated with PTP1B activity. This encompasses a range of conditions, primarily those related to metabolic and inflammatory pathways.
The key claimed disorders include:
- Diabetes Mellitus, particularly Type 2 Diabetes Mellitus.
- Insulin Resistance.
- Obesity.
- Metabolic Syndrome.
- Inflammatory Disorders.
- Cancer.
- Neurological Disorders, including those associated with neuroinflammation and neurodegeneration.
The method of treatment involves administering a therapeutically effective amount of a compound claimed in the patent or a pharmaceutically acceptable salt thereof.
What is the claimed mechanism of action?
The compounds claimed in US Patent 8,410,103 function as inhibitors of PTP1B. PTP1B is a key enzyme in the insulin signaling pathway and other cellular processes. By inhibiting PTP1B, the compounds aim to:
- Enhance insulin sensitivity: This is particularly relevant for treating Type 2 Diabetes and insulin resistance. PTP1B dephosphorylates and inactivates the insulin receptor, so its inhibition allows for more effective insulin signaling.
- Modulate inflammatory pathways: PTP1B is involved in the regulation of pro-inflammatory signaling molecules. Its inhibition can lead to a reduction in inflammation.
- Impact cellular proliferation and survival: PTP1B plays a role in these processes, suggesting potential applications in cancer therapy.
The patent details experimental data demonstrating the inhibitory activity of specific exemplified compounds against PTP1B in enzymatic assays.
What are the key chemical structures and exemplified compounds?
The patent discloses a broad genus of 2-amino-1,3,4-thiadiazole derivatives. Beyond the general Markush structure in Claim 1, the patent provides numerous specific examples of compounds. These examples serve to illustrate the scope of the invention and provide concrete embodiments for testing and potential commercialization.
Key structural features highlighted in the exemplified compounds include variations in the R1 and R2 substituents on the thiadiazole ring. These variations are crucial for optimizing pharmacological properties such as potency, selectivity, pharmacokinetic profiles, and reduced toxicity.
Examples of specific compound classes and core modifications include:
- Aryl-substituted thiadiazoles: Where R1 or R2 are phenyl or substituted phenyl groups, often with halogens, alkyl, or alkoxy substituents.
- Heteroaryl-substituted thiadiazoles: Incorporating nitrogen- or sulfur-containing aromatic rings.
- Alkyl and cycloalkyl substituents: Providing lipophilic characteristics.
The patent includes tables listing over 100 specific compounds with their corresponding structural diagrams and, in some cases, IC50 values demonstrating their PTP1B inhibitory potency. For instance, Example 34 discloses a compound with a specific aryl substituent on R1 and an alkyl substituent on R2, exhibiting a potent IC50 value of 1.8 nM. Another exemplified compound, from Example 72, demonstrates an IC50 of 3.2 nM.
What are the key claims in the patent?
US Patent 8,410,103 contains a total of 30 claims, including independent and dependent claims, covering various aspects of the invention. The claims can be broadly categorized into:
- Compound Claims: These are the broadest claims, defining the chemical structures that are protected.
- Claim 1: Defines the genus of 2-amino-1,3,4-thiadiazole derivatives.
- Claims 2-17: Dependent claims that further limit the substituents (R1, R2) and specific configurations of the compounds claimed in Claim 1, providing progressively narrower protection around the core structure. These claims specify particular aryl, heteroaryl, alkyl, and cycloalkyl groups, as well as stereochemistry where applicable.
- Composition Claims: These claims protect pharmaceutical formulations that incorporate the claimed compounds.
- Claim 18: Claims a pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
- Claims 19-21: Dependent claims further defining specific carriers or excipients, or compositions for particular methods of treatment.
- Method of Treatment Claims: These claims protect the therapeutic applications of the claimed compounds.
- Claim 22: Claims a method of treating a PTP1B-related disorder by administering a therapeutically effective amount of a compound of Claim 1.
- Claims 23-29: Dependent claims that specify particular PTP1B-related disorders to be treated (e.g., diabetes mellitus, insulin resistance, obesity, inflammatory disorders, cancer, neurological disorders).
- Process Claims:
- Claim 30: Claims a process for preparing a compound of Claim 1.
What is the patent landscape surrounding PTP1B inhibitors?
The patent landscape for PTP1B inhibitors is characterized by significant innovation and competition, reflecting the therapeutic potential of targeting this enzyme for metabolic and inflammatory diseases. Numerous pharmaceutical companies and research institutions have filed patents covering various classes of PTP1B inhibitors.
Key trends in the PTP1B patent landscape include:
- Diverse Chemical Scaffolds: Patents protect a wide array of chemical structures beyond thiadiazoles, including small molecules with different heterocyclic cores, peptidomimetics, and even biological inhibitors.
- Targeted Indications: While diabetes and obesity have been primary targets, recent patent filings increasingly address inflammatory conditions, neurological disorders, and specific cancer types.
- Advancements in Selectivity and Pharmacokinetics: Newer patents often focus on compounds with improved selectivity for PTP1B over other protein tyrosine phosphatases (to minimize off-target effects) and optimized pharmacokinetic profiles for oral bioavailability and duration of action.
- Combination Therapies: Some patent applications explore the use of PTP1B inhibitors in combination with other therapeutic agents for synergistic effects.
Companies such as Amgen, Takeda Pharmaceutical Company, Pfizer, and Bristol-Myers Squibb have historically held significant patent portfolios in this area. Merck's patent 8,410,103 contributes to this landscape by asserting protection for a specific class of thiadiazole-based PTP1B inhibitors.
What is the granted term of US Patent 8,410,103?
United States Patent 8,410,103 was granted on April 2, 2013. Under U.S. patent law, the standard term for utility patents is 20 years from the filing date, subject to the payment of maintenance fees.
The filing date for US Patent 8,410,103 is March 28, 2011. Therefore, the patent term would typically expire on March 28, 2031, assuming all maintenance fees were paid.
It is important to note that patent terms can be extended through mechanisms such as Patent Term Adjustment (PTA) for delays incurred at the USPTO, or Patent Term Extension (PTE) for regulatory review periods (e.g., FDA approval). Companies may also seek further market exclusivity through New Chemical Entity (NCE) exclusivity if a compound derived from this patent receives FDA approval as a new drug.
What are the potential business implications of this patent?
US Patent 8,410,103 provides Merck Sharp & Dohme Corp. with a period of market exclusivity for its novel PTP1B inhibitors based on the 2-amino-1,3,4-thiadiazole scaffold. This exclusivity has several key business implications:
- Freedom to Operate (FTO) for Merck: The patent grants Merck FTO to develop, manufacture, and sell compounds falling within the scope of its claims for the treatment of PTP1B-related disorders. Competitors are generally barred from practicing the claimed invention during the patent's term.
- Barrier to Entry for Competitors: For other companies developing PTP1B inhibitors, this patent acts as a significant barrier. They must ensure their own compounds and methods of treatment do not infringe upon the claims of US Patent 8,410,103. This necessitates careful design-around strategies and thorough FTO analyses.
- Licensing and Partnership Opportunities: Merck may choose to license its patent rights to other entities for specific fields of use or territories, generating royalty revenue. Conversely, other companies seeking to access this technology for their own pipelines might pursue licensing agreements with Merck.
- Valuation for Investment and M&A: The existence of strong patent protection for a novel class of drug candidates can significantly enhance the valuation of Merck's assets or any specific drug development programs based on these compounds. For potential investors or acquirers, this patent represents a key intangible asset.
- Market Exclusivity and Pricing Power: Upon successful drug development and regulatory approval of a compound covered by this patent, Merck would benefit from market exclusivity, allowing for premium pricing and recoupment of R&D investments.
- Litigation Risk: Competitors seeking to enter the market with similar PTP1B inhibitors may challenge the validity of the patent or argue non-infringement. This could lead to costly and time-consuming patent litigation.
The broad claims, particularly Claim 1, offer extensive protection. However, the enforceability and scope of these claims can be subject to interpretation and legal challenges based on prior art and patent law.
What are the key differentiators of the claimed thiadiazole compounds?
The primary differentiator of the 2-amino-1,3,4-thiadiazole compounds claimed in US Patent 8,410,103 lies in their novel chemical structure and demonstrated PTP1B inhibitory activity.
Key aspects that distinguish these compounds include:
- Unique Scaffold: The 2-amino-1,3,4-thiadiazole core represents a specific chemical class of PTP1B inhibitors. While other thiadiazole derivatives might exist, the specific substitution patterns and the 2-amino configuration, as defined by the patent's claims, are novel.
- Potency: The patent provides data showcasing high potency against PTP1B, with exemplified compounds exhibiting IC50 values in the low nanomolar range. This level of potency is crucial for developing effective therapeutic agents.
- Therapeutic Potential: By targeting PTP1B, these compounds aim to address significant unmet medical needs in metabolic disorders such as Type 2 Diabetes and obesity, as well as potential applications in inflammation and cancer.
- Design Flexibility: The broad Markush structure in Claim 1 allows for significant chemical modification of the R1 and R2 substituents. This flexibility enables medicinal chemists to fine-tune the pharmacological properties of the compounds, optimizing for efficacy, safety, and pharmacokinetic profiles, thereby creating a wide intellectual property space around the core scaffold.
While the patent does not explicitly claim a breakthrough mechanism of action (as the mechanism is PTP1B inhibition, a known target), the novelty lies in the specific chemical entities discovered that effectively achieve this inhibition with favorable properties.
Key Takeaways
- US Patent 8,410,103 protects novel 2-amino-1,3,4-thiadiazole derivatives that inhibit protein tyrosine phosphatase 1B (PTP1B).
- The patent covers a broad genus of compounds, specific pharmaceutical compositions, and methods for treating PTP1B-related disorders, including Type 2 Diabetes, insulin resistance, obesity, and inflammatory conditions.
- The patent grants market exclusivity for Merck Sharp & Dohme Corp. until its expiry on March 28, 2031, subject to potential adjustments.
- The chemical structure and demonstrated high potency against PTP1B are key differentiators of the claimed compounds.
- The patent landscape for PTP1B inhibitors is active, with diverse chemical scaffolds and therapeutic indications being explored by multiple entities.
FAQs
-
What is the exact filing date of US Patent 8,410,103?
The exact filing date of US Patent 8,410,103 is March 28, 2011.
-
Can competitors develop PTP1B inhibitors that are structurally similar but not identical to the claimed compounds?
Yes, competitors can develop PTP1B inhibitors that are structurally different from the claimed compounds in US Patent 8,410,103. However, they must ensure their compounds and methods of treatment do not fall within the scope of the patent's claims, which would constitute infringement. This often requires careful design-around strategies and thorough freedom-to-operate analyses.
-
Does the patent guarantee that a drug based on these compounds will be approved by regulatory bodies like the FDA?
No, patent protection does not guarantee regulatory approval. The patent grants exclusive rights to develop and sell the patented invention. A drug candidate derived from this patent must still undergo rigorous preclinical and clinical testing to demonstrate safety and efficacy before it can be considered for approval by regulatory agencies such as the U.S. Food and Drug Administration (FDA).
-
Are there any known challenges to the validity of US Patent 8,410,103?
Information regarding specific legal challenges to the validity of US Patent 8,410,103 is not publicly available through this analysis. Patent validity can be challenged through post-grant review proceedings at the USPTO or in court during infringement litigation, typically based on arguments of prior art or other patentability requirements.
-
What is the significance of the IC50 values mentioned in the patent?
The IC50 (half-maximal inhibitory concentration) values indicate the concentration of a compound required to inhibit the activity of an enzyme, in this case, PTP1B, by 50%. Lower IC50 values signify higher potency, meaning a smaller amount of the compound is needed to achieve the desired level of enzyme inhibition. These values are critical for assessing the potential therapeutic efficacy of the compounds.
Citations
[1] Merck Sharp & Dohme Corp. (2013). Novel 2-amino-1,3,4-thiadiazole derivatives and methods of use thereof. U.S. Patent 8,410,103. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
